Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study of BCX7353 for acute treatment of hereditary angioedema (HAE) attacks

Next Previous
Search
Trial Profile

Phase III study of BCX7353 for acute treatment of hereditary angioedema (HAE) attacks

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berotralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms ZENITH-2
  • Sponsors BioCryst Pharmaceuticals

    • Most Recent Events

    • 06 Aug 2019 According to a BioCryst Pharmaceuticals media release, the company plans to initiate this trial in 2020.
    • 28 Feb 2019 New trial record
    • 23 Feb 2019 According to a BioCryst Pharmaceuticals media release, company plans to initiate this study in the summer of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top